Free Trial
NASDAQ:MTSR

Metsera Q1 2025 Earnings Report

Metsera logo
$51.90 +0.20 (+0.39%)
As of 04:00 PM Eastern

Metsera EPS Results

Actual EPS
-$1.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Metsera Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Metsera Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
4:00PM ET

Metsera Earnings Headlines

Metsera, Inc. (MTSR) was downgraded to a Hold Rating at Wells Fargo
$3,600 gold is nice ... but here’s what most gold bugs are missing
Gold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet.tc pixel
Metsera Announces Positive Phase 2b Trial Results
Metsera (NASDAQ:MTSR) Upgraded by Wall Street Zen to "Hold" Rating
See More Metsera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Metsera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metsera and other key companies, straight to your email.

About Metsera

Metsera (NASDAQ:MTSR), Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

View Metsera Profile

More Earnings Resources from MarketBeat